Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia

  • Technology appraisal guidance
  • TA425
  • Published: 

Evidence

Documents containing the evidence that was used to develop the recommendations.

Supporting evidence